DC-D-134

DC-D-134 is a preclinical-stage Degrader Antibody Conjugate (DAC) being developed by Tubulis for the treatment of solid tumors. This therapeutic candidate represents an innovative modality that combines a monoclonal antibody with a protein degrader payload, designed to deliver the degrader moiety specifically to tumor cells where it induces targeted protein degradation. Unlike traditional antibody-drug conjugates (ADCs) that use cytotoxic payloads, DACs like DC-D-134 utilize degrader molecules (such as PROTACs or molecular glues) that trigger the intracellular degradation of disease-causing proteins through the ubiquitin-proteasome system. The specific biological target of DC-D-134 remains undisclosed by Tubulis. The compound is currently in the preclinical development phase and is part of Tubulis's broader pipeline leveraging their proprietary conjugation technologies to develop novel antibody conjugates for oncology applications.